Latest Developments in IP Strategies for Pharmaceuticals

Summer 2022

International Pharmaceutical Industry

By Sara A. Leiman, Ph.D.; Jordan M. Gringauz; Amanda K. Murphy, Ph.D.; Stacy Lewis*

The strategies used to create and maintain strong pharmaceutical patent portfolios must evolve with developments in the pharmaceutical space. These developments include not just scientific advancements but also requirements and practices of regulatory bodies, such as the United States Food and Drug Administration (FDA). This article addresses innovative prosecution strategies and useful considerations that may facilitate better agreement between pharmaceutical patent practice and FDA policy.

Read "Latest Developments in IP Strategies for Pharmaceuticals"

*Stacy Lewis is a Law Clerk at Finnegan.

Originally printed in International Pharmaceutical Industry in the Summer 2022 issue. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.